Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy - Contacts and Locations

Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

This study has been terminated.

Study NCT00079859. Last updated on June 23, 2005. Information provided by Medical Research Laboratories International

Please refer to this study by its ClinicalTrials.gov identifier: NCT00079859

Locations


United States, Ohio
	Metabolic and Atherosclerosis Research Center
	Cincinnati, Ohio, United States, 45229

Netherlands
	Andromed Oost
	Velp, Netherlands
	Andromed Rotterdam
	Rotterdam, Netherlands
	Andromed Leiden
	Leiden, Netherlands
	Andromed Zoetermeer
	Zoetermeer, Netherlands

Norway
	Lipidklinikken - Rikshospitalet
	Oslo, Norway

Sponsors and Collaborators

Medical Research Laboratories International